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The Social Insurance Institution, Research Department, Helsinki, FinlandA B S T R A C TObjectives: To analyze the medium- to long-term impact of generic
substitution and the reference price system on the daily cost of
antipsychotics in Finland. The additional impact of reference pricing
over and above previously implemented generic substitution was also
assessed. Methods: An interrupted time series design with a control
group and segmented regression analysis was used to estimate the
effect of the implementation of generic substitution and the reference
price system on the daily cost of antipsychotics. The data have 69
monthly values of the average daily cost for each of the studied
antipsychotics: 39 months before and 30 months after the introduc-
tion of reference pricing. For one of the studied antipsychotic, the
time before the introduction of reference pricing could be further
divided into time before and after the introduction of generic sub-
stitution. Results: According to the model, 2.5 years after the imple-
mentation of reference pricing, the daily cost of the studied
antipsychotics was 24.6% to 50.6% lower than it would have been ifee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.08.014
skinen@kela.ﬁ.
ondence to: Hanna Koskinen, The Social Insurancereference pricing had not been implemented. Two and a half years
after the implementation of the reference price system, however, the
additional impact of reference pricing over and above previously
implemented generic substitution was modest, less than 1
percentage point. Conclusions: Although the price competition
induced by reference pricing decreased the prices of antipsychotics
in Finland in the short-term, the prices had a tendency to stagnate or
even to turn in an upward direction in the medium- to long-term.
Furthermore, the additional impact of reference pricing over and
above previously implemented generic substitution remained quite
modest.
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pricing, segmented linear regression analysis.
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In most European countries, prescription medication costs are
subsidized by public or private health insurance schemes.
Because patients do not bear the full cost of their consumption,
prices have limited effect on their choice between different
treatments. This and the rising public pharmaceutical expendi-
tures have created a need for governments to regulate medicine
prices and demand in various ways [1,2]. One attractive steering
and cost-containment policy option for many governments has
been the promotion of the use of generic medicines through
generic substitution and a reference price system.
In generic substitution, pharmacies have the right or obliga-
tion to substitute the prescribed medicine with a cheaper equiv-
alent medicine [3]. Reference-based pricing, however, is a
reimbursement mechanism in which a third-party payer sets a
ceiling price for interchangeable pharmaceuticals belonging to
the same cluster. The clusters are based on generic groups,
related drug groups, or groups for drugs with similar therapeutic
effects. The ceiling price, or reference price, is based on, for
example, the lowest or the average price of products in thatcluster. Products priced at or below the reference price are
subsidized, whereas products above the reference price require
the patient to pay the excess in part or in total [2].
Although it is known that reference price systems are in the
short-term generally associated with decreases in prices covered
by the policy, studies examining the impact beyond the ﬁrst year
of implementation are lacking [2,4,5]. Furthermore, to our knowl-
edge, there is only one previous study that has been able to
differentiate between the impact of generic substitution and the
reference price system on prices. In that study from Finland, a
substantial decrease, ranging from 29.9% to 66.3%, was seen in
the daily cost of antipsychotics after 1 year of implementing the
reference price system. Because one of the studied antipsychotics
was already included in generic substitution over a year before
the reference pricing, it was observed that 75.3% of the total
decrease of 43.3% in the daily cost was generated by generic
substitution [6].
The aim of this study was to analyze the medium- to long-term
impact of generic substitution and a reference price system on the
daily cost of antipsychotics in Finland. The additional impact of
reference pricing over and above previously implemented genericociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Institution, Research Department, P.O. Box 450, 00101 Helsinki,
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 0 5 – 1 1 1 21106substitution was also assessed. We also report on the price
developments of one of the studied antipsychotics.
Pricing and Reimbursement of Pharmaceuticals in Finland
Finland adopted a reference price system in April 2009, whereas
generic substitution was introduced 6 years earlier, in April 2003.
Concurrent with the adoption of a generic reference price system,
the range of medicinal products available for generic substitution
was also extended. In Finland, it was not possible to grant
product patents for medicinal substances before 1995; only so-
called analogy process patents were possible. Although products
protected by an analogy process patent in Finland were initially
included in generic substitution, this decision was changed in
2006 when the Finnish Medicines Act was amended so that
pharmaceuticals were excluded from the generic substitution
system if they were protected by an analogous process patent in
Finland and had product patent protection in at least ﬁve other
European Economic Area countries. When a generic reference
price system was approved by the Finnish government, however,
the decision was again changed and it was decided that pharma-
ceuticals protected by an analogous process patent would again
be included in the sphere of generic substitution (Amendment
803/2008 on Medicines Act [395/1987]). This meant that products
protected by an analogy process patent could be included into
generic substitution in Finland even while the products were still
under patent protection in many other countries.
In the generic substitution system in Finland, pharmacies are
obligated to substitute a prescribed medicine with the cheapest or
close to the cheapest product containing the same active sub-
stance. Substitutable products contain the same active ingredient,
the same quantity, have the same route of administration, and
must be sold in comparable package sizes. The reference price
groups are based on the list of substitutable medicinal products
compiled by the Finnish Medicines Agency Fimea. The reference
prices are determined quarterly, and they are calculated by adding
€1.50 to the price of the most inexpensive product within the group
if the cheapest product is priced below €40.00. If the cheapest
product is priced at €40.00 or more, a sum of €2.00 is added.When a
product is included in a reference price group, however, a max-
imum wholesale price for the product is conﬁrmed. This price is
often around 40% lower than the price of the originator product but
generally higher than market prices [7]. That is to say that the
actual market prices and thus the reference prices are typically
lower than the conﬁrmed maximum wholesale prices.
When only generic substitution was in effect, either the
physician or the patient could veto the substitution without
affecting the reimbursement rate of the product. In the reference
price system, stronger monetary incentives for patients were
implemented. Patients who do not wish to switch to a cheaper
medicine are reimbursed according to the reference price, and
they must pay the excess themselves. If the substitution is vetoed
by the prescribing doctor, the reimbursement is calculated
according to the purchase price of the dispensed product [8]. In
Finland, there are three reimbursement categories: the basic
refund category (42% during the study years), lower special
reimbursement category (72% during the study years), and higher
special reimbursement category (a ﬁxed co-payment of €3.00 per
purchase and the rest is reimbursed at 100%).
Besides the implementation of generic substitution and refer-
ence pricing, the reimbursement system in Finland remained
substantially unchanged through the study period.
Antipsychotic Medication
Antipsychotics are primarily indicated for the treatment of
psychotic disorders such as bipolar disorder and schizophreniaand schizoaffective disorder. They were not originally included in
generic substitution in Finland because of concerns about com-
pliance [9]. This decision was later changed and from 2006
onward antipsychotics were considered to be substitutable,
provided they otherwise meet the criteria for substitutability.
In 2008, three antipsychotics—olanzapine, quetiapine, and
risperidone—accounted for 82% of the total reimbursed spending
on antipsychotic medications and more than 5% of the total
reimbursed pharmaceutical expenditure in Finland [10,11]. Two
of these antipsychotics—olanzapine and quetiapine—were pro-
tected by an analogy process patent. They were included into
generic substitution alongside the introduction of reference pric-
ing in April 2009, whereas the third, risperidone, had been
included in generic substitution already in January 2008. Aripi-
prazole is also an antipsychotic but in contrast to the three other
antipsychotics it was not included in the reference price system
because of its patent status during the study period.
In Finland, prescription drugs used in ambulatory care are
reimbursed under the National Health Insurance Scheme, which
covers all permanent residents in Finland. Antipsychotics can be
reimbursed either under the basic reimbursement category or
under the higher special refund category. To be entitled to receive
reimbursement under the higher special refund category, the
patient must be diagnosed with severe psychotic disorder [8]. On
average, the antipsychotic reimbursement rate was 92% in 2008.
Antipsychotics were chosen for this study because of their
high total costs and because different active substances within
the drug group were included in generic substitution and refer-
ence pricing at different times during the study period. More
speciﬁcally, olanzapine, quetiapine, and risperidone (the most
used atypical antipsychotics) were selected for this study,
whereas aripiprazole was used as a control group.Methods
The Social Insurance Institution of Finland maintains a national
register that contains information on medicine purchases that
have been reimbursed under the National Health Insurance
Scheme. About 94% of the antipsychotic medication consumption
sold by Finnish pharmacies is covered by the register. The data
extracted for this study consisted of reimbursed purchases of
olanzapine (Anatomical Therapeutic Chemical classiﬁcation [12]
code N05AH03), quetiapine (N05AH04), risperidone (N05AX08),
and aripiprazole (N05AX12) from January 1, 2006, to September
31, 2011. The data include information on the date of dispensing,
the Anatomical Therapeutic Chemical code of the product, total
cost of the purchase, and the number of deﬁned daily doses [12]
purchased. The concept of DDD was developed for drug con-
sumption statistics, and it represents the assumed typical daily
dose for a drug when used for its main indication in adults.
Because we had no information on actual daily doses of the
medication, we used DDD as a proxy for daily dose. Monthly
sums of costs and DDDs were calculated for each of the anti-
psychotics, and these sums were further calculated into monthly
average costs per DDD. The costs used are retail prices exclusive
of value-added tax, and they include both the National Health
Insurance Scheme’s reimbursement part of the price and the
patient’s own contributions.
To assess the effect of the implementation of generic sub-
stitution and the reference price system on the daily cost of
antipsychotics, we used an interrupted time series design with a
control group. Segmented regression analysis was applied to this
design. An interrupted time series is a strong quasi-experimental
design in which data are collected at multiple time points before
and after the intervention. The advantage of this design is that it
detects a possible underlying secular trend that could wrongly
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the preintervention control phase, the design can be further
strengthened by adding a control group that has not been
affected by the intervention. By comparing the effect on the
intervention group with that on the control group, it is possible
to separate the intervention effect from other interventions or
inﬂuences that may have occurred at the same time. In seg-
mented regression analysis, the time series is divided into
preintervention and postintervention segments. The model can
also specify more than one intervention. The idea of the model is
to estimate the level and trend of the outcome of interest in the
preintervention segment and then estimate the changes in the
level and trend in the subsequent postintervention segment or
segments. The results of the segmented regression model can be
presented as parameter estimates and as absolute and relative
differences between the estimated postintervention values of
the outcome at a given time point after the intervention
compared with an estimate based only on baseline level and
trend [13–15].
In our study material, we had 69 monthly values of the
average daily cost for each of the four antipsychotics: 39 months
before and 30 months after the introduction of reference pricing.
Although reference pricing was implemented simultaneously
with generic substitution for olanzapine and quetiapine, for
risperidone the 39 months before the introduction of reference
pricing could be further divided into 24 months before and 15
months after the introduction of generic substitution. Therefore,
the impact of these two policy changes could be analyzed
separately for risperidone. Aripiprazole was used as a control
group. For detailed information of the models used, see Appendix
1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.08.014.
In the olanzapine data, an abrupt increase in the daily cost of
olanzapine could be seen 15 months after the implementation of
reference pricing. This increase, which was not caused by any
health policy interventions, was included into the olanzapine
model as a second change point, the ﬁrst being the implementa-
tion of reference pricing.
The normality and homoscedasticity of the residuals were
checked by statistical tests, and graphic analysis of residuals was
done to provide information about the consistency. This analysis
indicated the possibility of heteroscedasticity in the olanzapine
data. A scatter plot of time points and residuals suggested that
the variable time might be the source of heteroscedasticity.
Therefore, a model without a time variable was also ﬁtted in
the olanzapine data.Table 1 – The impact of simultaneously implemented ge
cost of olanzapine and the difference compared with the
Variable Olanzapine
Coefﬁcient
(€)
95% CI
Baseline level 4.6485 4.56164.7354
Trend before reference pricing,
per month
–0.0086 –0.0123 to –0.005
Level change after reference
pricing
–1.5251 –1.6686 to –1.381
Trend change after reference
pricing, per month
–0.0893 –0.1063 to –0.072
Level change after price increase 1.4940 1.3409 1.6471
Trend change after price increase,
per month
0.1143 0.0872 0.1414
NS, not signiﬁcant.In the risperidone data, an outlier was detected. The outlier
was identiﬁed as December 2007, indicating that marketing
authorization holders (MAHs) were anticipating the forthcoming
generic substitution by decreasing prices already 1 month before
the implementation of the system. A dummy variable estimating
the pre-effect to generic substitution was constructed for the
risperidone model.
Because error terms may be correlated in time series data, the
Durbin-Watson test was applied. Autocorrelation was detected in
all the data sets, and thus autoregressive error models were used
to estimate the regression parameters with control of autocorre-
lation. Autoregressive parameters up to 13 months were included
in the model.
The estimations were done using maximum likelihood meth-
ods [15,16]. A backward-stepwise elimination with a signiﬁcance
level of 0.05 was used to obtain the most parsimonious models.
The conﬁdence intervals for absolute and relative changes in the
daily cost were calculated using bootstrap methods with 10,000
iterations [6,15]. All analyses were conducted using SAS 9.2 [17].Results
Between January 1, 2006, and September 31, 2011, there were
525,995 purchases of olanzapine, 1,083,610 purchases of quetia-
pine, 710,456 purchases of risperidone, and 97,833 purchases of
aripiprazole.
Olanzapine
The baseline daily cost of olanzapine was €4.65. There was a
statistically signiﬁcant downward month-to-month prereference
cost trend, though there was no statistically signiﬁcant difference
compared with aripiprazole (Table 1). Immediately after reference
pricing was introduced, the level of the daily cost fell substan-
tially and the month-to-month downward trend accelerated.
Fifteen months after the implementation of reference pricing
in July 2010, an abrupt and considerable increase in the daily cost
of olanzapine could be seen. Also, the month-to-month trend
shifted from a downward direction to an upward direction. This
phenomenon differed statistically signiﬁcantly from aripiprazole
and was not a result of any other policy changes. Further
investigation established that the phenomenon was explained
by changes in the number of MAHs operating in the olanzapine
market. Up to April 2009, one MAH had in practise nearly a
monopoly position in the olanzapine market. At the initiation of
the reference price system, there were four MAHs in theneric substitution and reference pricing on the daily
control drug aripiprazole.
Olanzapine relative to aripiprazole
P Coefﬁcient
(€)
95% CI P
o0.0001   NS
0 o0.0001   NS
6 o0.0001 1.5812 1.38411.7783 o0.0001
3 o0.0001 0.0908 0.06900.1126 o0.0001
o0.0001 –1.5236 –1.7401 to –1.3071 o0.0001
o0.0001 –0.1322 –0.1702 to –0.0942 o0.0001
F
a
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MAHs were engaged in price competition. This changed in June
2010, however, when one of the three MAHs was forced to exit
the market because of patent protection issues. Although the
price competition between three MAHs had forced the reference
price lower than the conﬁrmed maximum wholesale prices, the
two remaining MAHs raised their prices immediately to match
the conﬁrmed wholesale price of the remaining generic product.
The originator brand’s patent expired internationally in Octo-
ber 2011. This meant that more MAHs entered the Finnish
market, which restarted the price competition. According to the
model, at the end of the study period, the daily cost of olanzapine
was estimated to be €3.06 whereas it would have been €4.05
without the implementation of reference pricing (Fig. 1). This
represents an absolute reduction of €1.00 and a relative reduction
of 24.6% in the daily cost of olanzapine (Table 4). Because the
scatter plot of time points and residuals suggested the possibility
of heteroscedasticity, the consistency of the estimates was
checked by omitting the time variable from the model. The
results proved to be robust.
Quetiapine
The baseline daily cost of quetiapine was €5.63 (Table 2). There
was a downward month-to-month trend before reference pricing
was implemented, and this trend accelerated after reference
pricing (Fig. 2). Both trends before and after the implementation
of reference pricing differed statistically signiﬁcantly from the
control group aripiprazole. Immediately after reference pricing
was implemented, the daily cost of quetiapine dropped substan-
tially. According to the model, after 2.5 years of the implementa-
tion of reference pricing, the daily cost of quetiapine was €1.97
lower in absolute terms and 50.6% lower in relative terms than it
would have been if reference pricing had not been implemented
(Table 4).
Risperidone
The baseline level of the daily cost of risperidone was €5.82.
There was a slight but statistically signiﬁcant upward trend
before generic substitution was implemented, but this trend
turned downward after generic substitution (Table 3). A substan-
tial drop in the daily cost could be seen 1 month before generic0,0
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nd the subsequent MAHs’ price increase not been implementedsubstitution was implemented. Although the cost rose slightly
following the pre-effect, the implementation of generic substitu-
tion still had a substantial effect on the daily cost of risperidone.
A further abrupt drop could be seen when reference pricing was
implemented, but after that the month-to-month trend shifted
from a downward direction to an upward direction (Fig. 3). All the
estimates differed statistically signiﬁcantly from those of the
control group aripiprazole.
After 2.5 years of implementing the reference pricing, the
daily cost of risperidone was estimated to be €4.02, whereas if no
intervention had been implemented, the daily cost would have
been €7.11. In absolute terms, that represents a reduction of €3.09
and in relative terms a reduction of 43.4%. If only generic
substitution and no reference pricing would have been imple-
mented, the estimated daily cost of risperidone would have been
€4.05 at the end of the study period. That corresponds to an
absolute reduction of €3.06 and a relative reduction of 43.0%
(Table 4). Therefore, after 2.5 years, the additional impact of the
reference price system over and above the impact of previously
implemented generic substitution was very small, at only 0.4
percentage points.Discussion
Consistent with earlier research, this study showed that the
introduction of a reference price system is associated with a
decrease in the prices of medicines subject to the policy. Our
study also pointed out, however, that most of the impact is seen
immediately after implementation, and after a typically abrupt
drop, the prices have a tendency to stagnate or even to turn to a
slightly upward direction.
For quetiapine and risperidone, the relative reduction in the
daily cost 2.5 years after the implementation of generic substitu-
tion and reference pricing was approximately of the same size.
The drugs differ, however, in that the policy measures were
implemented simultaneously for quetiapine, whereas for risper-
idone, generic substitution was implemented about a year before
reference pricing. According to our study, after 2.5 years, the
additional impact of reference pricing on top of previously
implemented generic substitution was very small, at only about
0.4 percentage point. Thus, it seems that though the reference price
system is associated with price decreases, generic substitution cann 0
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(€). MAH, marketing authorization holder.
Table 2 – The impact of simultaneously implemented generic substitution and reference pricing on the daily
cost of quetiapine and the difference compared with control drug aripiprazole.
Variable Quetiapine Quetiapine relative to aripiprazole
Coefﬁcient
(€)
95% CI P Coefﬁcient
(€)
95% CI P
Baseline level 5.6360 5.50945.7626 o0.0001 –0.9923 –1.1715 to –0.8131 o0.0001
Trend before reference pricing,
per month
–0.0254 –0.0306 to –0.0202 o0.0001 0.0179 0.01050.0253 o0.0001
Level change after reference
pricing
–1.1326 –1.2509 to –1.0143 o0.0001 1.1633 0.99591.3307 o0.0001
Trend change after reference
pricing, per month
–0.0278 –0.0386 to –0.0170 o0.0001 0.0211 0.00580.0364 0.0071
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 0 5 – 1 1 1 2 1109alone be effective in promoting price competition. Nonetheless,
although the additional impact of reference pricing to previ-
ously implemented generic substitution had waned after 2.5
years of implementation, substantial savings had been gained
during that time. This result is in line with earlier ﬁndings
demonstrating that health care reforms aimed at cost contain-
ment are typically successful, though with gradually diminish-
ing results [18].
Although earlier studies have indicated that reference pricing
produces more signiﬁcant price decreases in the submarkets
where medicines were already facing generic competition before
reference pricing [4], this presumption does not seem to hold
entirely in this study. There are, however, some factors that
might inﬂuence the generalizability of our result. For example,
the adopted reference price scheme and the size of the market
can inﬂuence the economic viability of MAHs to enter the market
and take part in price competition. Also, earlier studies have
indicated that the probability of generic entry depends on the fact
whether the originator product lowers its price to reference price
values [4]. Furthermore, external reference pricing, a practice of
using the price(s) of a medicine in another country or countries to
set or negotiate the price in a given country [19], can have a
signiﬁcant impact on MAHs’ pricing behavior. In the European
area, authorities oftentimes refer to prices in other countries
when making reimbursement and pricing decisions. Thus, low
prices in one country can make it harder to justify higher prices
in other countries. Because the size of the pharmaceutical market
in Finland is relatively small, MAHs’ pricing decisions in Finland
are generally dependent on international prices. This can have aTable 3 – The impact of separately implemented generic
risperidone and the difference compared with the contro
Variable Risperidone
Coefﬁcient
(€)
95% CI
Baseline level 5.8167 5.75385.8796
Trend before generic substitution,
per month
0.0187 0.01390.0235
Pre-effect to generic substitution –1.2413 –1.3820 to –1.100
Level change after generic
substitution
–1.1233 –1.2375 to –1.009
Trend change after generic
substitution, per month
–0.0430 –0.0533 to –0.032
Level change after reference
pricing
–0.8114 –0.9084 to –0.714
Trend change after reference
pricing, per month
0.0261 0.0162–0.0360signiﬁcant impact on companies’ ability to engage in price
competition in Finland.
The global ﬁnancial crisis that Europe has been dealing with
since 2008 put extra pressure on pharmaceutical spending and
consumption. Indeed, in response to the economic recession,
most European countries implemented some type of measures to
contain public expenditure on pharmaceuticals. Because many of
the taken measures, such as reference pricing, affect patients’
out-of-pocket expenses, there was a fear that the consumption of
needed pharmaceuticals would decrease to a point where
patients’ well-being might be at risk. This might be especially
important with therapeutic groups such as antipsychotics to
which patients are often regarded as particularly vulnerable
and economically disadvantaged. A study looking at the impact
of economic recession on 10 highest-selling therapeutic drug
classes in eight European countries, including Finland, found that
although the value of sales declined, the volume was maintained
[20,21]. A study looking speciﬁcally at the impact of policy
interventions on the utilization of antipsychotic medicines in
times of economic recession in Finland and Portugal, however,
found that there was a slight decrease in the overall use of
antipsychotic medicines [22].
The reference price system has been found to be effective in
decreasing prices of medicines in the short-term both across
different countries and regulatory systems and across generic
and therapeutic reference price schemes [4]. In this respect, the
results of our study support earlier ﬁndings. Because there are no
previous studies, however, looking at the impact of the reference
price system on prices in the longer run and only one short-termsubstitution and reference pricing on the daily cost of
l drug aripiprazole.
Risperidone relative to aripiprazole
P Coefﬁcient
(€)
95% CI P
o0.0001 –1.0179 –1.1070 to –0.9288 o0.0001
o0.0001 –0.0380 –0.0447 to –0.0313 o0.0001
6 o0.0001 1.2970 1.0979 1.4961 o0.0001
1 o0.0001 1.1408 0.9793 1.3023 o0.0001
7 o0.0001 0.0643 0.0497– 0.0789 o0.0001
4 o0.0001 0.9266 0.7896– 1.0636 o0.0001
o0.0001 –0.0489 –0.0629 to –0.0349 o0.0001
F
n
Table 4 – Absolute and relative impacts of the interventions on the average daily cost, estimated from the
regression models.
Active ingredient Daily cost with
intervention(s)
(€)
Daily cost without
intervention(s) (€)
Absolute change Relative change
€ 95% CI % 95% CI
Olanzapine, both GS and RP 3.0579 4.0535 –0.9956 –1.2463 to –0.7702 –24.6 –29.8 to –19.6
Quetiapine, both GS and RP 1.9168 3.8834 –1.9666 –2.2959 to –1.6386 –50.6 –56.0 to –44.6
Risperidone, both GS and RP 4.0203 7.1070 –3.0867 –3.3622 to –2.8090 –43.4 –45.6 to –41.1
Risperidone, only GS 4.0487 7.1070 –3.0583 –3.4834 to –2.6319 –43.0 –48.4 to –37.6
GS, generic substitution; RP, reference pricing.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 0 5 – 1 1 1 21110study [6] that has isolated the impact of the reference price
system from the impact of generic substitution, it is difﬁcult to
estimate how generalizable our results are in that respect. For
example, the length of a reference price period might inﬂuence
MAHs’ willingness to take part in price competition. In Finland,
reference prices are set every 3 months, whereas MAHs can
change the prices of their products every 2 weeks. It is possible
that this rather long reference price period combined with the
possibility of change in prices every 2 weeks allows companies to
watch and wait instead of actively taking part in the price
competition. In Denmark, for example, the reference prices are
based on the price of the cheapest product within the substitu-
tion group and change every 2 weeks [23].
For the generic medicine industry to deliver and sustain
competitive prices, it must be ensured a high volume of the
pharmaceutical market [24]. Although the number of marketing
authorizations issued to generic medicines in Finland has
increased steadily, by volume the market share of generic
medicines was only 36% in 2011, the equivalent of 15% by value
[3,25–27]. For example, in Denmark, which has a very mature
generics market, generics accounted for 72% by volume and 24%
by value in 2011. The corresponding ﬁgures for another mature
generics market, the United Kingdom, were 75% and 28%,
respectively [27]. These comparisons support ﬁndings that coun-
tries with high generic market share have typically larger
decreases in medicine prices than do countries with low generic
market share [28]. Besides reference pricing, possible measures to0
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ot been implemented (€).promote the use of generic products and price competition
include tenders and auctions. These measures are particularly
used in hospital settings. Relatively little evidence is available on
the value of tendering in the ambulatory sector [29].
This study highlights a potential weakness in the Finnish
reference price system. All reimbursed products are granted a
maximum wholesale price in Finland. The price is the max-
imum price for which wholesalers can sell the product to the
pharmacies. For products included in the reference price sys-
tem, the maximum price is not reviewed by authorities once
included. This means that though price competition in most
cases decreases actual prices and reference prices below the
conﬁrmed maximum wholesale prices, MAHs operating in
submarkets with low competition have always an opportunity
to optimize and raise their prices to match the maximum
wholesale prices. This was observed in the olanzapine case in
which 15 months after the implementation of the reference
price system two MAHs raised their prices simultaneously to
match the conﬁrmed wholesale price of the generic product.
This was possible because, due to patent protection issues, the
third MAH in the market was forced to exit. Although the
increase in the olanzapine prices was only temporary and price
competition was jump-started again when more MAHs entered
the market, from the perspective of the third-party payer and
the patient, considerable potential savings during the period
were lost. Similar negative implications have also been
observed in The Netherlands, where setting-guaranteedn 0
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Fig. 3 – Observed and predicted daily cost of risperidone and the forecast cost had generic substitution and reference pricing
not been implemented (€).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 0 5 – 1 1 1 2 1111reimbursement ceilings for reference groups provided no incen-
tive for MAHs to set a price below the ceiling level. In fact, the
prices of several generic drugs were raised toward the max-
imum reimbursement level [30].
A major strength of this study is that it is based on a national
prescription register that covers reimbursed purchases of anti-
psychotics during the whole study period. A further strength
relates to the methods used in the study. An interrupted time
series design is the strongest quasi-experimental approach for
evaluating longitudinal effects of interventions, whereas seg-
mented regression analysis is a powerful statistical method for
estimating intervention effects in interrupted time series studies
[13]. Our study was further strengthened by including into the
analysis a control group not subject to the policy changes.Conclusions
This study demonstrated that although the price competition
induced by reference pricing generated substantial savings in the
antipsychotics expenditure in Finland in the short-term, the
prices had a tendency to stagnate or even to turn in an upward
direction in the medium- to long-term. Furthermore, the addi-
tional impact of reference pricing over and above previously
implemented generic substitution remained at the very least
modest in the medium- to long-term.Acknowledgments
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